FIELD: medicine.
SUBSTANCE: single intravitreal introduction of an aqueous solution of human recombinant vascular endothelial growth factor 3.5 mcg is provided.
EFFECT: enabling the adequate neovascularisation, preferentially within cornea and ciliary body - iris root, over a short period of time with minimal injuries and reduced price of the experiment.
7 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR STIMULATING NEOVASCULARISATION OF RETINA AND OPTIC NERVE IN RABBITS | 2009 |
|
RU2408083C1 |
| METHOD FOR SIMULATING DIABETIC MACULAR NEOVASCULARISATION | 2012 |
|
RU2504844C1 |
| PHARMACEUTICAL ANTIANGIOGENIC COMPOSITION FOR TREATING EYE DISEASES | 2013 |
|
RU2526825C1 |
| METHOD OF COMBINED TREATMENT OF SEVERE FORMS OF SECONDARY NEOVASCULAR GLAUCOMA | 2019 |
|
RU2708059C1 |
| METHOD FOR COMBINED TREATMENT OF SECONDARY NEOVASCULAR OPEN-ANGLE GLAUCOMA | 2022 |
|
RU2786145C1 |
| AGENT INHIBITING ANGIOGENESIS IN VISUAL ORGAN DISEASE | 2001 |
|
RU2177801C1 |
| METHOD OF TREATING SECONDARY NEOVASCULAR GLAUCOMA | 2009 |
|
RU2411969C1 |
| METHOD OF COMBINED TREATMENT OF SECONDARY NEOVASCULAR GLAUCOMA AT EARLY STAGES | 2019 |
|
RU2708045C1 |
| METHOD FOR PREVENTION OF HAEMORRHAGIC COMPLICATIONS IN SURGICAL MANAGEMENT OF PATIENTS WITH SECONDARY NEOVASCULAR UNCOMPENSATED GLAUCOMA | 2024 |
|
RU2840443C1 |
| INTEGRIN RECEPTOR ANTAGONISTS AND USE THEREOF | 2012 |
|
RU2721907C2 |
